[go: up one dir, main page]

CA2024381A1 - Composes de xanthine - Google Patents

Composes de xanthine

Info

Publication number
CA2024381A1
CA2024381A1 CA2024381A CA2024381A CA2024381A1 CA 2024381 A1 CA2024381 A1 CA 2024381A1 CA 2024381 A CA2024381 A CA 2024381A CA 2024381 A CA2024381 A CA 2024381A CA 2024381 A1 CA2024381 A1 CA 2024381A1
Authority
CA
Canada
Prior art keywords
chem
effect
independently represents
renal
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2024381A
Other languages
English (en)
Other versions
CA2024381C (fr
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Tetsuji Ohno
Akira Karasawa
Kazuhiro Kubo
Hiromi Nonaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of CA2024381A1 publication Critical patent/CA2024381A1/fr
Application granted granted Critical
Publication of CA2024381C publication Critical patent/CA2024381C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002024381A 1989-09-01 1990-08-31 Composes de xanthine Expired - Fee Related CA2024381C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22664289 1989-09-01
JP226642/89 1989-09-01

Publications (2)

Publication Number Publication Date
CA2024381A1 true CA2024381A1 (fr) 1991-03-02
CA2024381C CA2024381C (fr) 1997-01-07

Family

ID=16848383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002024381A Expired - Fee Related CA2024381C (fr) 1989-09-01 1990-08-31 Composes de xanthine

Country Status (10)

Country Link
EP (1) EP0415456B1 (fr)
JP (1) JPH06102662B2 (fr)
AT (1) ATE139778T1 (fr)
BR (1) BR1100762A (fr)
CA (1) CA2024381C (fr)
CY (1) CY2069B1 (fr)
DE (1) DE69027562T2 (fr)
DK (1) DK0415456T3 (fr)
ES (1) ES2091212T3 (fr)
GR (1) GR3020715T3 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (fr) * 1991-02-25 1992-08-26 Fumio Suzuki Composes de la xanthine
ATE180482T1 (de) * 1991-11-08 1999-06-15 Kyowa Hakko Kogyo Kk Xanthinderivate zur behandlung der demenz
US5336769A (en) * 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (fr) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
WO1995031460A1 (fr) * 1994-05-17 1995-11-23 Kyowa Hakko Kogyo Co., Ltd. Procede pour produire un derive de xanthine
JP2001523213A (ja) 1994-12-13 2001-11-20 ユーロ−セルティーク，エス．エイ． 三置換チオキサンチン類
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
ATE247116T1 (de) 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
WO1998057644A1 (fr) * 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Agent de prevention et remede contre la nephropathie induite par les medicaments
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0970696A1 (fr) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Composition comprenant des diurétiques d'anse et des antagonists des recepteurs A1 de l'adenosine
ATE342734T1 (de) * 1998-06-01 2006-11-15 Astellas Pharma Inc Adenosin a1 antagonisten gegen männliche sterilität
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
EE200200248A (et) 1999-11-12 2003-06-16 Biogen, Inc. Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid
ES2323357T3 (es) * 1999-11-12 2009-07-14 Biogen Idec Ma Inc. Policicloalquilpurinas como antagonistas del receptor de adenosina.
EP1510222A3 (fr) 2000-04-26 2007-05-23 Eisai R&D Management Co., Ltd. Compositions medicinales favorisant les mouvements intestinaux
UA75625C2 (en) 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
EP1513848A4 (fr) * 2002-06-12 2005-11-09 Biogen Idec Inc Procede de traitement des lesions consecutives a la perfusion ischemique au moyen des antagonistes de recepteurs d'adenosine
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
WO2004106337A1 (fr) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Derives de xanthine servant d'antagonistes du recepteur de l'adenosine a2b
JP4769721B2 (ja) * 2003-08-25 2011-09-07 トロヴィス ファーマシューティカルズ リミテッド ライアビリティ カンパニー 置換８−ヘテロアリールキサンチン
EP1961422A1 (fr) 2005-12-14 2008-08-27 Kyowa Hakko Kogyo Co., Ltd. Préparation orale facilement absorbée contenant un dérivé de la xanthine
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
GB8618931D0 (en) * 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung

Also Published As

Publication number Publication date
EP0415456A2 (fr) 1991-03-06
EP0415456A3 (en) 1991-05-29
ATE139778T1 (de) 1996-07-15
JPH03173889A (ja) 1991-07-29
DE69027562T2 (de) 1997-02-20
JPH06102662B2 (ja) 1994-12-14
DE69027562D1 (de) 1996-08-01
BR1100762A (pt) 2000-03-14
CY2069B1 (en) 1998-09-11
HK1000600A1 (en) 1998-04-09
DK0415456T3 (da) 1996-07-29
GR3020715T3 (en) 1996-11-30
CA2024381C (fr) 1997-01-07
ES2091212T3 (es) 1996-11-01
EP0415456B1 (fr) 1996-06-26

Similar Documents

Publication Publication Date Title
CA2024381A1 (fr) Composes de xanthine
GR3020369T3 (en) Xanthine derivatives
CA2124680A1 (fr) Derives piperazine utilises comme antagonistes de 5-ht1a
EP0031567A3 (fr) Dérivés de tétrapeptidesemicarbazide, leur production et leur utilisation
PL263885A1 (en) Method of obtaining novel derivatives of dihydrobenzofurane and chromate carbonamide
IL114785A0 (en) Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them
PL249964A1 (en) Process for preparing novel derivatives of 7-//z/-2-/2-aminothiazolyl-4/-2-oxyiminoacetamide/-3-cephemo-4-carboxylic acid
ATE71944T1 (de) Thiazolderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
GR3002692T3 (en) Benzoxazine derivatives and processes for preparation thereof
HUT54362A (en) Process for producing cumarin derivatives and pharmaceutical compositions containing them
EP0331078A3 (fr) Procédé de préparation de dérivés optiquement actifs de l'acide 4-oxo-benzopyranne-2-carboxylique et leurs intermédiaires
ES8604185A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,5-benzotiazepina.
DE68900990D1 (en) Thioformamid-derivate.
EP0347880A3 (fr) Composés d'imidazo[2,1-b]benzothiazole et compositions anti-ulcère les contenant
GR3007219T3 (fr)
TW262467B (fr)
AU2014188A (en) Naphthothiazepine derivatives and preparation thereof
AU4370489A (en) The use of oxidized polyamines, especially nn'-bis-(3- propionaldehyde)-1-4-diaminobutane (sperminedialdehyde) as immunosuppressive agents
PH25608A (en) 3-amino-tetrahydro-isoquinoline
MY101746A (en) 1,5-benzothiazepine derivatives, a process for preparing the same, pharmaceutical compositions as well as the use thereof.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed